non-Hodgkin lymphoma
AACR: Affimed builds case for natural killer cell therapy
Phil Taylor
Affimed, bispecific antibody, classical Hodgkin lymphoma, immuno-oncology, natural killer cell, non-Hodgkin lymphoma, Oncology
0 Comment
Roche closes in on first-line use for lymphoma drug Polivy in Europe
Phil Taylor
antibody-drug conjugate, diffuse B-Cell lymphoma, Haematology, non-Hodgkin lymphoma, Oncology, Polivy, Roche
0 Comment
ASH: Trial backs Gilead’s Yescarta CAR-T in first-line lymphoma
Phil Taylor
CAR-T therapies, Gilead Sciences, immuno-oncology, non-Hodgkin lymphoma, Oncology, Yescarta
0 Comment
ASH: Gilead, BMS CAR-Ts square off in relapsed lymphoma
Phil Taylor
Breyanzi, Bristol-Myers Squibb, Gilead Sciences, immuno-oncology, non-Hodgkin lymphoma, Oncology, Yescarta
0 Comment
ASH abstract drop backs Roche’s Polivy in first-line lymphoma
Phil Taylor
antibody-drug conjugate, DLBCL, Haematology, non-Hodgkin lymphoma, Oncology, Polivy, Roche
0 Comment
Incyte, MorphoSys’ CAR-T rival tafasitamab approved in EU
Phil Taylor
CAR-T therapies, EU, Incyte, MorphoSys, non-Hodgkin lymphoma, regulatory approval, tafasitamab
0 Comment
Novartis’ bid to extend Kymriah into earlier use hits a roadblock
Phil Taylor
CAR-T therapies, diffuse B-Cell lymphoma, immuno-oncology, Kymriah, non-Hodgkin lymphoma, Novartis, Oncology
0 Comment
Armed with phase 3 data, Roche preps filing for Polivy in first-line DLBCL
Phil Taylor
antibody-drug conjugate, DLBCL, Haematology, non-Hodgkin lymphoma, Oncology, Polivy, Roche
0 Comment